Immunotherapy in soft tissue sarcoma: current evidence and future perspectives in a variegated family of different tumor-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Immunotherapy in soft tissue sarcoma: current evidence and future perspectives in a variegated family of different tumor

Published:2022-04-26 Issue:5 Volume:22 Page:491-503
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Baldi Giacomo G¹,Gronchi Alessandro²^ORCID,Tazzari Marcella³,Stacchiotti Silvia⁴

Affiliation:

1. Department of Medical Oncology, Hospital of Prato, Prato, Italy

2. Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

3. Immunotherapy, Cell Therapy and Biobank Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy

4. Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy

Funder

no funding to report

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737140.2022.2065986

Reference106 articles.

1. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

2. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

3. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

4. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

5. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Spatial distribution of tumour immune infiltrate predicts outcomes of patients with high-risk soft tissue sarcomas after neoadjuvant chemotherapy;eBioMedicine;2024-08

2. Long Duration Pembrolizumab for Metastatic Undifferentiated Pleomorphic Soft Tissue Sarcoma With Multimodality Therapy;Journal of Medical Cases;2024-07

3. Extremity and Truncal Soft Tissue Sarcoma: Risk Assessment and Multidisciplinary Management;Seminars in Radiation Oncology;2024-04

4. Combining nanoparticle albumin-bound paclitaxel with camrelizumab in advanced soft tissue sarcoma: activity, safety, and future perspectives;Frontiers in Pharmacology;2024-02-01

5. Targeting EZH2 in SMARCB1-deficient sarcomas: Advances and opportunities to potentiate the efficacy of EZH2 inhibitors;Biochemical Pharmacology;2023-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3